Immunogenicity of Antibody Therapeutics

Handbook of Therapeutic Antibodies

Volumn 1, Issue , 2008, Pages 267-276

  Schellekens, Huub ^a   Crommelin, Daan ^b   Jiskoot, Wim ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Humira; Hybridoma technology; Mabthera; Xolair; Zenapax

Indexed keywords

EID: 84889410578     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch11     Document Type: Chapter

References (30)

1. Baert, F., Noman, M., Vermeire, S., van Assche, G., D'Haens, G., Carbonez, A., Rutgeerts, P. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
2. Bradbury, A. (1999) Display technologies expand their horizons. Trends Biotechnol 17: 137-138.
3. Buist, M.R., Kenemans, P., van Kamp, G.J., Haisma, H.J. (1995) Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 40: 24-30.
4. Chakerian, B., Lenz, P., Lowy, D.R., Schiller, J.T. (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169: 6120-6126.
5. Chapman, A.P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54: 531-545.
6. Clark, M. (2000) Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 21: 397-402.
7. El Kasmi, K.C., Deroo, S., Theisen, D.M., Brons, N.H.C., Muller, C.P. (2000) Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict cross reactive immunogenicity. Vaccine 18: 284-290.
8. Fagnani, R., Halpern, S., Hagan, M. (1995) Altered pharmacokinetic and tumour localization properties of Fab' fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran. Nucl Med Commun 16: 362-369.
9. Gonzales, N.R., Schuck, P., Schlom, J., Kashmiri, S.V.S. (2002) Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. J Immunol Methods 268: 197-210.
10. Goodnow, C.C. (2001) Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 357: 2115-2121.
11. Hanauer, S.B. (2003) Immunogenicity of infliximab in Crohn's disease. N Engl J Med 348: 2155-2156.
12. Hwang, W.Y.K., Foote, J. (2005) Immunogenicity of engineered antibodies. Methods 36: 3-10.
13. Isaacs, J.D. (2001) From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology 40: 724-738.
14. Iwahashi, M., Milenic, D.E., Padlan, E.A., Bei, R., Schlom, J., Kashmiri, S.V.S. (1999) CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 36: 1079-1091.
15. Kellerman, S.A., Green, L.L. (2002) Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13: 593-597.
16. Kohler, G., Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
17. Koprowski, H., Herlyn, D., Lubeck, M., DeFreitas, M., Sears, H.F. (1984) Human anti-idiotype antibodies in ancer patients: is the modulation of the immune response beneficial for the patient. Proc Natl Acad Sci USA 81: 216-219.
18. Kuus-Reichel, K., Grauer, L.S., Karavodin, L.M., Knott, C., Krusemeier, M., Kay, N.E. (1994) Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1: 365-372.
19. Livingston, P.O., Adluri, S., Zhang, S., Chapman, P., Raychaudhuri, S., Merritt, J. A. (1995) Impact of immunological adjuvants and administration route on HAMA respones after immunication with murine monoclonal antibody MELIMMUNE-1 in melanoma patients. Vac Res 4: 87-94.
20. Merluzzi, S., Figini, M., Colombatti, A., Canevari, S., Pucillo, C. (2000) Humanized antibodies as potential drugs for therapeutic use. Adv Clin Pathol 4: 77-85.
21. Pendley, C., Schantz, A., Wagner, C. (2003) Immunogenicity of therpeutic monoclonal antibodies. Curr Opin Mol Ther 5: 172-179.
22. Reff, M.E., Heard, C. (2001) A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Oncol/Hematol 40: 25-35.
23. Ritter, G., Cohen, L.S., Williams, C., Richards, E.C., Old, L.J., Welt, S. (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61: 6851-6859.
24. Schellekens, H. (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24: 1720-1740.
25. Stephens, S., Emtage, S., Vetterlein, O., Chaplin, L., Bebbington, C., Nesbitt, A., Sopwith, M., Athwall, D., Noval, C., Bodmer, M. (1995) Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85: 668-674.
26. Taylor, P.C. (2003) Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3: 323-328.
27. Thurmond, L.M., Reese, M.J., Donaldson, R.J., Orban, B.S. (1998) A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum. J Pharm Biomed Anal 16: 1317-1328.
28. Trakas, N., Tzartos, S.J. (2001) Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity. J Neuroimmunol 120: 42-49.
29. Wagner, V., Reinsberg, J., Oehr, P., Briele, B., Schmidt, S., Werner, A., Krebs, D., Biersack, H.J. (1990) Clinical course of patients with ovarian arcinoma after induction of anti-idiotypic antibodies against tumor-associated antigen. Tumor Diagn Ther 11: 1-4.
30. Yang, X., Jia, X., Corvalan, J.R.F., Wang, P., Davis, C.G. (2001) Development of ABXEGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol/Hematol 38: 17-23.